1
|
Russo JJ, Yan AT, Pocock SJ, Brieger D, Owen R, Andersson Sundell K, Granger CB, Cohen MG, Yasuda S, Nicolau JC, Brandrup-Wognsen G, Westermann D, Simon T, Goodman SG. P1932Predictors of DAPT use in patients beyond 1 year post myocardial infarction: Insights from the TIGRIS observational study. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0679] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
International guidelines vary in their recommendations for dual antiplatelet therapy (DAPT) use beyond 1 year post-myocardial infarction (MI).
Purpose
To identify predictors of DAPT use in patients ≥1 year post-MI prior to the publication of the DAPT score and the 2017 European Society of Cardiology (ESC) guidelines for DAPT in coronary artery disease.
Methods
TIGRIS (NCT01866904) was a prospective, multi-center (369 centers in 25 countries), observational study of patients 1 to 3 years post-MI between June 2013 and November 2014. We performed a multivariable logistic regression analysis to identify independent predictors of DAPT use at 396 days post-MI (365 + 31 days overrun period to allow intended DAPT discontinuation at 1 year). Patients on oral anticoagulation were excluded.
Results
Of 8464 patients enrolled (mean age 66 years, women 24%, ST-elevation MI 53%), 40% were on DAPT at 396 days post-MI (Figure). In the subset of patients on DAPT at 396 days post-MI, aspirin was combined with clopidogrel in 84%, prasugrel in 12%, and other antiplatelet agents in 4%. DAPT use at 396 days post-MI was independently associated with geographic region, age, PCI for the index MI, and a history of multivessel disease or angina (Table). Several variables included in the DAPT score and ESC guideline recommendations (diabetes, second prior MI, hypertension, peripheral artery disease, heart failure, smoking, and renal insufficiency) were not independent predictors of DAPT use at 396 days.
Independent predictors of DAPT @396 days Variable at enrolment Patients Odds ratio (95% CI) P-value Region: Europe 3813 Reference group 0.01 North America 923 1.65 (0.56, 4.86) Latin America 1084 2.55 (1.19, 5.47) Asia and Australia 2644 3.01 (1.42, 6.36) Age <65 years 3274 1.15 (1.04, 1.28) 0.005 PCI for index MI 6925 2.08 (1.82, 2.38) <0.0001 Multi-vessel disease 5598 1.37 (1.24, 1.52) <0.0001 History of angina 829 1.46 (1.24, 1.71) <0.0001
DAPT use at 396 days post-MI by region
Conclusion
During the study period, DAPT use ≥1 year post-MI was prevalent and appeared to be influenced by regional practices. Further research is needed to determine whether the DAPT score and the 2017 ESC guidelines for dual antiplatelet therapy have changed long-term DAPT use practices.
Acknowledgement/Funding
AstraZeneca AB, Södertälje, Sweden
Collapse
Affiliation(s)
- J J Russo
- University of Ottawa Heart Institute, Ottawa, Canada
| | - A T Yan
- St Michael's Hospital, University of Toronto, Toronto, Canada
| | - S J Pocock
- London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - D Brieger
- Concord Repatriation General Hospital, Sydney, Australia
| | - R Owen
- London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - K Andersson Sundell
- AstraZeneca, Medical Evidence and Observational Research, Gothenburg, Sweden
| | - C B Granger
- Duke Clinical Research Institute, Durham, United States of America
| | - M G Cohen
- University of Miami Hospital, Miami, United States of America
| | - S Yasuda
- National Cerebral and Cardiovascular Center, Osaka, Japan
| | - J C Nicolau
- Heart Institute of the University of Sao Paulo (InCor), Sao Paulo, Brazil
| | - G Brandrup-Wognsen
- AstraZeneca, Medical Evidence and Observational Research, Gothenburg, Sweden
| | - D Westermann
- University Heart Center Hamburg, Hamburg, Germany
| | - T Simon
- Assistance Publique-Hopitaux de Paris (APHP), UPMC-Paris 06 University, Paris, France
| | - S G Goodman
- Canadian Heart Research Centre and St. Michael's Hospital, University of Toronto, Toronto, Canada
| |
Collapse
|
2
|
Terenzi DC, Verma S, Trac JZ, Quan A, Mason T, Al-Omran M, Dhingra N, Leiter LA, Zinman B, Yan AT, Connelly KA, Teoh H, Mazer CD, Hess DA. P317A novel role of SGLT2 inhibitors to increase circulating proangiogenic progenitor cells in patients with type 2 diabetes and cardiovascular disease: A sub-study of the EMPA-HEART CardioLink-6 Trial. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz747.0152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
SGLT2 inhibitors (SGLT2i) have been demonstrated to reduce major adverse cardiovascular events and mortality in patients with type 2 diabetes (T2D) who are at high risk for cardiovascular disease (CVD). However, the mechanism(s) of the underlying benefit remain unclear. Since regenerative cell exhaustion resulting in impaired vascular homeostasis has been proposed as a key driver of CV events in T2D, we hypothesised that modulation of circulating vascular regenerative cell content by SGLT2i may be a novel basis of cardioprotection.
Purpose
To evaluate the effects of the SGLT2i, empagliflozin (EMPA), vs placebo on circulating vascular regenerative and pro-inflammatory cells in patients with T2D and CVD.
Methods
This was a biomarker sub-study of the EMPA-HEART Cardiolink-6 randomised trial of EMPA (10mg QD) vs placebo in patients with T2D and a history of coronary artery disease (prior myocardial infarction and/or coronary revascularisation). Blood samples (baseline N=48; study end N=26) underwent multiparametric progenitor cell analyses by flow cytometry. Circulating cells were assessed for aldehyde dehydrogenase (ALDH) activity, a self-protective enzyme highly expressed in several proangiogenic progenitor cell lineages, as well as cell surface co-expression of the primitive progenitor (CD34, CD133) or M1/M2 macrophage (CD80, CD163) markers.
Results
Individuals with increased inflammatory burden (ALDHhi granulocytes above the baseline median) were older (61±2 vs 67±2 years), more likely to be current or past smokers (21% vs 42%) and had reduced LV function, assessed by echocardiography. The placebo- and EMPA-assigned groups were equivalent at baseline with respect to the frequency and distribution of proangiogenic progenitor cells (ALDHhiSSClo), monocyte/macrophage (ALDHhiSSCmid) and inflammatory granulocyte (ALDHhiSSChi) precursors. Following 6-months of treatment with EMPA, there was a marked increase in the number of circulating primitive ALDHhiSSClo cells with CD133 (Placebo: −2.8±3.8%, EMPA: +8.6±2.5%, P<0.02) or CD133/CD34 (Placebo: 0.4±4.5%, EMPA: +13.3±3.8%, P<0.05) co-expression. Furthermore, EMPA treatment was associated with an increase in the frequency of circulating anti-inflammatory cells with M2 macrophage polarisation marked by CD163 (Placebo: −0.7±0.8%, EMPA = +3.9±1.3%, P<0.01) expression. Non-significant increases in circulating proangiogenic monocytes, and decreases in the frequency of circulating inflammatory granulocytes were also observed after EMPA treatment (vs placebo).
Conclusion
We provide the first evidence showing that SGLT2i treatment with EMPA alters the balance of key circulating vascular progenitor and inflammatory cells in patients with T2D and CVD. We suggest that SGLT2i may afford cardioprotection through a novel and previously unrecognised capacity to limit regenerative cell exhaustion in T2D.
Acknowledgement/Funding
This trial was supported by an unrestricted investigator-initiated study grant from Boehringer Ingelheim.
Collapse
Affiliation(s)
- D C Terenzi
- St. Michael's Hospital, Cardiac Surgery, Toronto, Canada
| | - S Verma
- St. Michael's Hospital, Cardiac Surgery, Toronto, Canada
| | - J Z Trac
- St. Michael's Hospital, Cardiac Surgery, Toronto, Canada
| | - A Quan
- St. Michael's Hospital, Cardiac Surgery, Toronto, Canada
| | - T Mason
- St. Michael's Hospital, Cardiac Surgery, Toronto, Canada
| | - M Al-Omran
- St. Michael's Hospital, Vascular Surgery, Toronto, Canada
| | - N Dhingra
- St. Michael's Hospital, Cardiac Surgery, Toronto, Canada
| | - L A Leiter
- St. Michael's Hospital, Endocrinology & Metabolism, Toronto, Canada
| | - B Zinman
- Mount Sinai Hospital of the University Health Network, Endocrinology & Metabolism, Toronto, Canada
| | - A T Yan
- St. Michael's Hospital, Cardiology, Toronto, Canada
| | - K A Connelly
- St. Michael's Hospital, Cardiology, Toronto, Canada
| | - H Teoh
- St. Michael's Hospital, Cardiac Surgery, Toronto, Canada
| | - C D Mazer
- St. Michael's Hospital, Anesthesia, Toronto, Canada
| | - D A Hess
- University of Western Ontario, Physiology and Pharmacology, London, Canada
| |
Collapse
|
3
|
Garg V, Verma S, Connelly KA, Yan AT, Sikand A, Garg A, Dorian P, Zuo F, Leiter LA, Zinman B, Juni P, Verma A, Quan A, Mazer CD, Ha ACT. P3753Does empagliflozin modulate the autonomic system among patients with type 2 diabetes and coronary artery disease? Insights from the Holter sub-study of the EMPA-Heart CardioLink-6 Randomised Trial. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0605] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
The mechanism behind how empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, reduces all-cause and cardiovascular mortality among patients with type 2 diabetes (T2DM) and coronary artery disease (CAD) is unknown. Autonomic tone, as reflected by changes in heart rate variability (HRV), is an established prognosticator in patients with CAD and/or heart failure.
Purpose
To assess if empagliflozin treatment changes HRV in subjects with T2DM and CAD.
Methods
In the double-blind EMPA-Heart trial, 97 subjects with T2DM and CAD were randomised to empagliflozin 10 mg/day or placebo for 6 months and underwent 24-hour Holter monitoring at baseline and 6 months. Using automated algorithms, time and frequency HRV domain measures were obtained (standard deviation of NN intervals (SDNN); SD of the average NN intervals for each 5-minute segment (SDANN); root mean square of successive RR interval differences (rMSSD); % interval differences of successive NN intervals >50 ms (pNN50); ratio of low to high frequency (LF/HF)). Changes of these HRV parameters were calculated over 6 months. Between-group differences in HRV parameters were compared using ANCOVA.
Results
Complete Holter data (baseline and 6-month) were available for 68% (n=66) of the cohort. The average heart rate (HR) at baseline/6 months was 69.5±9.8 bpm/72.8±8.1 bpm and 76±10.4 bpm/76.5±10.6 in the placebo group and empagliflozin group, respectively. Both groups had similar changes in average HR over 6 months. Key Holter data are summarised in the table. SDNN and SDANN were higher in the placebo vs. empagliflozin group at 6 months; no significant difference was noted for all other measures.
Empagliflozin 10 mg/day (n=33) Placebo (n=33) Adjusted difference between Empagliflozin and Placebo (ANCOVA) Baseline, Mean (SD) 6-month, Mean (SD) Baseline, Mean (SD) 6-month, Mean (SD) Mean, (95% CI) P-value SDNN (ms) 100.49 (43.74) 98.05 (38.86) 109.35 (30.02) 125.08 (43.83) −18.55 (−34.28, −2.82) 0.022 SDANN (ms) 86.84 (39.34) 83.76 (35.53) 94.70 (28.52) 118.28 (77.41) −20.24 (−37.27, −3.21) 0.021 rMSSD (ms) 27.00 (11.84) 27.22 (13.48) 28.00 (11.58) 27.17 (9.38) −1.23 (−6.02, 3.55) 0.608 pNN50 (%) 7.81 (7.59) 8.32 (9.51) 8.26 (7.8) 6.93 (5.35) 0.51 (−2.61, 3.62) 0.746 LF/HF ratio 1.63 (0.52) 1.65 (0.51) 1.53 (0.43) 1.83 (0.82) −0.08 (−0.38, 0.22) 0.602
Conclusions
Among subjects with T2DM and CAD, changes in HRV over 6 months were similar in the empagliflozin and placebo arms suggesting that the mortality benefit conferred by empagliflozin is not associated with positive modulation of autonomic tone.
Acknowledgement/Funding
This trial was supported by an unrestricted investigator-initiated study grant from Boehringer Ingelheim.
Collapse
Affiliation(s)
- V Garg
- St. Michael's Hospital, Cardiac Surgery, Toronto, Canada
| | - S Verma
- St. Michael's Hospital, Cardiac Surgery, Toronto, Canada
| | - K A Connelly
- St. Michael's Hospital, Cardiology, Toronto, Canada
| | - A T Yan
- St. Michael's Hospital, Cardiology, Toronto, Canada
| | - A Sikand
- St. Michael's Hospital, Cardiac Surgery, Toronto, Canada
| | - A Garg
- University of Toronto, Medicine, Toronto, Canada
| | - P Dorian
- St. Michael's Hospital, Cardiology, Toronto, Canada
| | - F Zuo
- St. Michael's Hospital, Applied Health Research Centre, Toronto, Canada
| | - L A Leiter
- St. Michael's Hospital, Endocrinology & Metabolism, Toronto, Canada
| | - B Zinman
- Mount Sinai Hospital of the University Health Network, Endocrinology & Metabolism, Toronto, Canada
| | - P Juni
- St. Michael's Hospital, Applied Health Research Centre, Toronto, Canada
| | - A Verma
- Southlake Regional Health Centre, Cardiology, Toronto, Canada
| | - A Quan
- St. Michael's Hospital, Cardiac Surgery, Toronto, Canada
| | - C D Mazer
- St. Michael's Hospital, Anesthesia, Toronto, Canada
| | - A C T Ha
- UHN - University of Toronto, Peter Munk Cardiac Centre, Toronto, Canada
| |
Collapse
|
4
|
Konieczny K, Banks L, Osman W, Glibbery M, Connelly KA, Yan AT, Goodman JM, Dorian P. Prolonged P wave duration is associated with right atrial dimensions, but not atrial arrhythmias, in middle-aged endurance athletes. J Electrocardiol 2019; 56:115-120. [PMID: 31394411 DOI: 10.1016/j.jelectrocard.2019.07.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2019] [Revised: 06/28/2019] [Accepted: 07/06/2019] [Indexed: 11/19/2022]
Abstract
BACKGROUND Atrial arrhythmias occur at a higher than expected prevalence amongst endurance athletes. Few studies have examined both atrial structure and arrhythmias in middle-aged endurance athletes. We examined the relationship between P-wave duration, atrial dimensions, and the presence of atrial ectopy in long-standing, middle-aged endurance athletes. METHODS Middle-aged athletes with a minimum of 10 years of competitive endurance sport history and no history of structural heart disease or clinical atrial arrhythmias, had 12-lead ECGs to assess P-wave duration, signal-averaged ECGs (SAECG) to assess filtered P-wave duration, a 24 h Holter monitor to assess atrial ectopy, and echocardiography and cardiac magnetic resonance imaging to assess atrial structural characteristics. RESULTS Amongst endurance athletes (n = 104; mean age = 54 ± 5 years; 63% male), filtered P-wave duration on SAECG was correlated with P-wave duration on 12-lead ECG (r = 0.36, p, 0.0001), as well as with larger CMR-derived RA areas (r = 0.30, p = 0.01) and volumes (r = 0.24, p < 0.05). There was no correlation between filtered P-wave duration and any LA measures on imaging (p > 0.05). There was no correlation between the incidence of atrial ectopy (premature atrial contractions or atrial tachycardia) and any electrocardiographic or structural measures. CONCLUSION Longer filtered P-wave duration was associated with larger RA areas and volumes, without an increase in atrial ectopy.
Collapse
Affiliation(s)
- K Konieczny
- Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
| | - L Banks
- Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, Ontario, Canada
| | - W Osman
- Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
| | - M Glibbery
- Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, Ontario, Canada
| | - K A Connelly
- Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
| | - A T Yan
- Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
| | - J M Goodman
- Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, Ontario, Canada; Division of Cardiology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
| | - P Dorian
- Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
| |
Collapse
|
5
|
Verma S, Mazer DC, Bhatt DL, Raj SR, Yan AT, Verma A, Ferrannini E, Simons G, Lee J, Zinman B, George JT, Fitchett D. P1876Empagliflozin reduces mortality in patients with type 2 diabetes and a history of left ventricular hypertrophy: a sub-analysis of the EMPA-REG OUTCOME trial. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p1876] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- S Verma
- St Michael's Hospital, Division of Cardiac Surgery, University of Toronto, Toronto, Canada
| | - D C Mazer
- St Michael's Hospital, Department of Anesthesia, University of Toronto, Toronto, Canada
| | - D L Bhatt
- Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston, United States of America
| | - S R Raj
- Vanderbilt University, Division of Clinical Pharmacology, Nashville, United States of America
| | - A T Yan
- St Michael's Hospital, Division of Cardiology, University of Toronto, Toronto, Canada
| | - A Verma
- St Michael's Hospital, Division of Cardiac Surgery, University of Toronto, Toronto, Canada
| | - E Ferrannini
- University of Pisa School of Medicine, Pisa, Italy
| | - G Simons
- Boehringer Ingelheim International GmbH, Ingelheim, Germany
| | - J Lee
- Boehringer Ingelheim International GmbH, Ingelheim, Germany
| | - B Zinman
- Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Canada
| | - J T George
- Boehringer Ingelheim International GmbH, Ingelheim, Germany
| | - D Fitchett
- St Michael's Hospital, Division of Cardiology, University of Toronto, Toronto, Canada
| |
Collapse
|
6
|
Wilson WM, Walsh SJ, Bagnall A, Yan AT, Hanratty CG, Egred M, Smith E, Oldroyd KG, McEntegart M, Irving J, Douglas H, Strange J, Spratt JC. One-year outcomes after successful chronic total occlusion percutaneous coronary intervention: The impact of dissection re-entry techniques. Catheter Cardiovasc Interv 2017; 90:703-712. [PMID: 28296045 DOI: 10.1002/ccd.26980] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/10/2016] [Revised: 01/07/2017] [Accepted: 01/17/2017] [Indexed: 11/10/2022]
Abstract
We aimed to determine clinical outcomes 1 year after successful chronic total occlusion (CTO) PCI and, in particular, whether use of dissection and re-entry strategies affects clinical outcomes. Hybrid approaches have increased the procedural success of CTO percutaneous coronary intervention (PCI) but longer-term outcomes are unknown, particularly in relation to dissection and re-entry techniques. Data were collected for consecutive CTO PCIs performed by hybrid-trained operators from 7 United Kingdom (UK) centres between 2012 and 2014. The primary endpoint (death, myocardial infarction, unplanned target vessel revascularization) was measured at 12 months along with angina status. One-year follow up data were available for 96% of successful cases (n = 805). In total, 85% of patients had a CCS angina class of 2-4 prior to CTO PCI. Final successful procedural strategy was antegrade wire escalation 48%; antegrade dissection and re-entry (ADR) 21%; retrograde wire escalation 5%; retrograde dissection and re-entry (RDR) 26%. Overall, 47% of CTOs were recanalized using dissection and re-entry strategies. During a mean follow up of 11.5 ± 3.8 months, the primary endpoint occurred in 8.6% (n = 69) of patients (10.3% (n = 39/375) in DART group and 7.0% (n = 30/430) in wire-based cases). The majority of patients (88%) had no or minimal angina (CCS class 0 or 1). ADR and RDR were used more frequently in more complex cases with greater disease burden, however, the only independent predictor of the primary endpoint was lesion length. CTO PCI in complex lesions using the hybrid approach is safe, effective and has a low one-year adverse event rate. The method used to recanalize arteries was not associated with adverse outcomes. © 2017 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- W M Wilson
- Royal Melbourne Hospital, Department of Cardiology, Parkville VIC 3050, Melbourne, Australia
| | - S J Walsh
- Department of Cardiology, Belfast Health and Social Care Trust, Belfast, Ireland
| | - A Bagnall
- Freeman Hospital, Cardiothoracic Services, Newcastle upon Tyne, England.,Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, England
| | - A T Yan
- Division Cardiology, St Michael's Hospital, University of Toronto, Canada
| | - C G Hanratty
- Department of Cardiology, Belfast Health and Social Care Trust, Belfast, Ireland
| | - M Egred
- Freeman Hospital, Cardiothoracic Services, Newcastle upon Tyne, England.,Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, England
| | - E Smith
- The London Chest Hospital, Barts Health NHS Trust, London, England, United Kingdom
| | - K G Oldroyd
- Golden Jubilee National Hospital, West of Scotland Regional Heart and Lung Centre, Glasgow, Scotland
| | - M McEntegart
- Golden Jubilee National Hospital, West of Scotland Regional Heart and Lung Centre, Glasgow, Scotland
| | - J Irving
- Ninewells Hospital, Dundee, Scotland
| | - H Douglas
- Department of Cardiology, Belfast Health and Social Care Trust, Belfast, Ireland
| | - J Strange
- Bristol Heart Institute, Bristol, United Kingdom
| | - J C Spratt
- Forth Valley Royal Hospital, Larbert, United Kingdom
| |
Collapse
|
7
|
Dondo TB, Hall M, Timmis AD, Yan AT, Batin PD, Oliver G, Alabas OA, Norman P, Deanfield JE, Bloor K, Hemingway H, Gale CP. Geographic variation in the treatment of non-ST-segment myocardial infarction in the English National Health Service: a cohort study. BMJ Open 2016; 6:e011600. [PMID: 27406646 PMCID: PMC4947744 DOI: 10.1136/bmjopen-2016-011600] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
OBJECTIVES To investigate geographic variation in guideline-indicated treatments for non-ST-elevation myocardial infarction (NSTEMI) in the English National Health Service (NHS). DESIGN Cohort study using registry data from the Myocardial Ischaemia National Audit Project. SETTING All Clinical Commissioning Groups (CCGs) (n=211) in the English NHS. PARTICIPANTS 357 228 patients with NSTEMI between 1 January 2003 and 30 June 2013. MAIN OUTCOME MEASURE Proportion of eligible NSTEMI who received all eligible guideline-indicated treatments (optimal care) according to the date of guideline publication. RESULTS The proportion of NSTEMI who received optimal care was low (48 257/357 228; 13.5%) and varied between CCGs (median 12.8%, IQR 0.7-18.1%). The greatest geographic variation was for aldosterone antagonists (16.7%, 0.0-40.0%) and least for use of an ECG (96.7%, 92.5-98.7%). The highest rates of care were for acute aspirin (median 92.8%, IQR 88.6-97.1%), and aspirin (90.1%, 85.1-93.3%) and statins (86.4%, 82.3-91.2%) at hospital discharge. The lowest rates were for smoking cessation advice (median 11.6%, IQR 8.7-16.6%), dietary advice (32.4%, 23.9-41.7%) and the prescription of P2Y12 inhibitors (39.7%, 32.4-46.9%). After adjustment for case mix, nearly all (99.6%) of the variation was due to between-hospital differences (median 64.7%, IQR 57.4-70.0%; between-hospital variance: 1.92, 95% CI 1.51 to 2.44; interclass correlation 0.996, 95% CI 0.976 to 0.999). CONCLUSIONS Across the English NHS, the optimal use of guideline-indicated treatments for NSTEMI was low. Variation in the use of specific treatments for NSTEMI was mostly explained by between-hospital differences in care. Performance-based commissioning may increase the use of NSTEMI treatments and, therefore, reduce premature cardiovascular deaths. TRIAL REGISTRATION NUMBER NCT02436187.
Collapse
Affiliation(s)
- T B Dondo
- Leeds Institute of Cardiovascular and Metabolic Medicine, Leeds, UK
| | - M Hall
- Leeds Institute of Cardiovascular and Metabolic Medicine, Leeds, UK
| | - A D Timmis
- The National Institute for Health Biomedical Research Unit, Barts Health, London, UK
| | - A T Yan
- Department of Medicine, University of Toronto, Toronto, Ontario, Canada
| | - P D Batin
- Department of Cardiology, The Mid Yorkshire Hospitals NHS Trust, Wakefield, UK
| | - G Oliver
- National Health Service cardiac service user, West Yorkshire, UK
| | - O A Alabas
- Leeds Institute of Cardiovascular and Metabolic Medicine, Leeds, UK
| | - P Norman
- School of Geography, University of Leeds, Leeds, UK
| | - J E Deanfield
- National Institute for Cardiovascular Outcomes Research, University College London, London, UK
| | - K Bloor
- Department of Health Sciences, University of York, York, UK
| | - H Hemingway
- The Farr Institute, University College London, London, UK
| | - C P Gale
- Leeds Institute of Cardiovascular and Metabolic Medicine, Leeds, UK
- York Teaching Hospital NHS Foundation Trust, York, UK
| |
Collapse
|
8
|
Wilson WM, Walsh SJ, Yan AT, Hanratty CG, Bagnall AJ, Egred M, Smith E, Oldroyd KG, McEntegart M, Irving J, Strange J, Douglas H, Spratt JC. Hybrid approach improves success of chronic total occlusion angioplasty. Heart 2016; 102:1486-93. [DOI: 10.1136/heartjnl-2015-308891] [Citation(s) in RCA: 127] [Impact Index Per Article: 15.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/04/2015] [Accepted: 04/16/2016] [Indexed: 11/04/2022] Open
|
9
|
Austin D, Yan AT, Jamieson S, Zaman AG, Kunadian V, Bagnall AJ. Treatment delay in primary PCI in relation to marital status and distance from acute medical care. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht307.p469] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
10
|
Bugiardini R, Yan AT, Yan RT, Fitchett D, Langer A, Manfrini O, Goodman SG. Factors influencing underutilization of evidence-based therapies in women. Eur Heart J 2011; 32:1337-1344. [DOI: 10.1093/eurheartj/ehr027] [Citation(s) in RCA: 139] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 08/30/2023] Open
|
11
|
Yan AT, Yan RT, Cantor WJ, Borgundvaag B, Cohen EA, Fitchett DH, Dzavik V, Ducas J, Tan M, Casanova A, Goodman SG. Relationship between risk stratification at admission and treatment effects of early invasive management following fibrinolysis: insights from the Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). Eur Heart J 2011; 32:1994-2002. [DOI: 10.1093/eurheartj/ehr008] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
|
12
|
Jolly SS, Shenkman H, Brieger D, Fox KA, Yan AT, Eagle KA, Steg PG, Lim KD, Quill A, Goodman SG. Quantitative troponin and death, cardiogenic shock, cardiac arrest and new heart failure in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS): insights from the Global Registry of Acute Coronary Events. Heart 2010; 97:197-202. [DOI: 10.1136/hrt.2010.195511] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
13
|
Yan RT, Yan AT, Mahaffey KW, White HD, Pieper K, Sun JL, Pepine CJ, Biasucci LM, Gulba DC, Lopez-Sendon J, Goodman SG. Prognostic utility of quantifying evolutionary ST-segment depression on early follow-up electrocardiogram in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J 2009; 31:958-66. [DOI: 10.1093/eurheartj/ehp548] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
|
14
|
Yan AT, Yan RT, Jedrzkiewicz S, Goodman SG. Evaluation of risk scores for risk stratification of acute coronary syndromes. Heart 2009; 95:1019-1020. [PMID: 19478112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/27/2023] Open
|
15
|
Vijayaraghavan R, Yan AT, Tan M, Fitchett DH, Georgescu AA, Hassan Q, Langer A, Goodman SG. Local hospital vs. core-laboratory interpretation of the admission electrocardiogram in acute coronary syndromes: increased mortality in patients with unrecognized ST-elevation myocardial infarction. Eur Heart J 2007; 29:31-7. [DOI: 10.1093/eurheartj/ehm503] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
16
|
Yan AT, Yan RT, Goodman SG. Are acute coronary syndromes risk models too complex? reply. Eur Heart J 2007. [DOI: 10.1093/eurheartj/ehm280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
17
|
Abstract
Congestive heart failure (CHF) is a serious medical condition frequently associated with sleep-related breathing disorders, which remain underdiagnosed and undertreated. Recent studies have provided important insight into the pathophysiology of sleep apnea syndrome in patients with CHF, with potential therapeutic implications. In addition to abolition of sleep apnea, continuous positive airway pressure (CPAP) treatment can improve cardiac function and relieve symptoms of CHF. Postulated mechanisms include beneficial hemodynamic effects on ventricular remodeling, unloading of fatigued respiratory muscles, and neurohormonal modulation. Although medium-term studies using CPAP to treat sleep-related breathing disorders associated with CHF have been encouraging, more definitive data from ongoing large clinical trials are necessary to clarify its therapeutic role.
Collapse
Affiliation(s)
- A T Yan
- Heart and Stroke/Richard Lewar Centre of Excellence, University of Toronto, Toronto, Ontario, Canada
| | | | | |
Collapse
|